Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 62.05
(0.98%)
EUR 62.05
(0.98%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 220.25 Million EUR | -13.91% |
| 2022 | 255.84 Million EUR | 40.91% |
| 2021 | 181.57 Million EUR | 143.13% |
| 2020 | 74.68 Million EUR | 74.32% |
| 2019 | 42.84 Million EUR | 145.41% |
| 2018 | 17.45 Million EUR | -8.16% |
| 2017 | 19 Million EUR | -32.83% |
| 2016 | 28.3 Million EUR | 29.57% |
| 2015 | 21.84 Million EUR | -21.13% |
| 2014 | 27.69 Million EUR | 8.72% |
| 2013 | 25.47 Million EUR | 17.51% |
| 2012 | 21.67 Million EUR | 14.18% |
| 2011 | 18.98 Million EUR | -26.99% |
| 2010 | 26 Million EUR | 87.09% |
| 2009 | 13.89 Million EUR | -50.92% |
| 2008 | 28.32 Million EUR | 53.6% |
| 2007 | 18.43 Million EUR | 427.86% |
| 2006 | 3.49 Million EUR | -100.0% |
| 2005 | 291.58 Billion EUR | 46495.19% |
| 2004 | 625.79 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 37.18 Million EUR | 92.69% |
| 2024 Q1 | 19.29 Million EUR | -71.13% |
| 2023 FY | 220.25 Million EUR | -13.91% |
| 2023 Q2 | 24.47 Million EUR | -59.69% |
| 2023 Q1 | 60.72 Million EUR | -38.67% |
| 2023 Q4 | 66.84 Million EUR | -1.99% |
| 2023 Q3 | 68.2 Million EUR | 178.62% |
| 2022 Q4 | 99.01 Million EUR | 88.71% |
| 2022 FY | 255.84 Million EUR | 40.91% |
| 2022 Q1 | 68.7 Million EUR | 17.88% |
| 2022 Q2 | 35.65 Million EUR | -48.11% |
| 2022 Q3 | 52.47 Million EUR | 47.16% |
| 2021 Q4 | 58.28 Million EUR | -2.94% |
| 2021 FY | 181.57 Million EUR | 143.13% |
| 2021 Q1 | 29.6 Million EUR | 52.56% |
| 2021 Q2 | 33.63 Million EUR | 13.61% |
| 2021 Q3 | 60.04 Million EUR | 78.54% |
| 2020 Q3 | 22.38 Million EUR | 26.04% |
| 2020 FY | 74.68 Million EUR | 74.32% |
| 2020 Q1 | 15.13 Million EUR | 73.26% |
| 2020 Q2 | 17.76 Million EUR | 17.37% |
| 2020 Q4 | 19.4 Million EUR | -13.31% |
| 2019 Q2 | 10.22 Million EUR | 35.69% |
| 2019 Q4 | 8.73 Million EUR | -46.61% |
| 2019 FY | 42.84 Million EUR | 145.41% |
| 2019 Q1 | 7.53 Million EUR | 1856.36% |
| 2019 Q3 | 16.35 Million EUR | 60.06% |
| 2018 Q4 | 385 Thousand EUR | -95.99% |
| 2018 Q3 | 9.59 Million EUR | 4555.34% |
| 2018 Q2 | 206 Thousand EUR | -97.17% |
| 2018 Q1 | 7.27 Million EUR | 1087.11% |
| 2018 FY | 17.45 Million EUR | -8.16% |
| 2017 FY | 19 Million EUR | -32.83% |
| 2017 Q4 | 613 Thousand EUR | 58.81% |
| 2017 Q3 | 386 Thousand EUR | -96.39% |
| 2017 Q2 | 10.7 Million EUR | 46.44% |
| 2017 Q1 | 7.3 Million EUR | 39.87% |
| 2016 Q2 | 9.25 Million EUR | -10.73% |
| 2016 Q1 | 10.37 Million EUR | 170.24% |
| 2016 FY | 28.3 Million EUR | 29.57% |
| 2016 Q3 | 3.44 Million EUR | -62.8% |
| 2016 Q4 | 5.22 Million EUR | 51.71% |
| 2015 Q1 | 7.14 Million EUR | 35.03% |
| 2015 FY | 21.84 Million EUR | -21.13% |
| 2015 Q4 | 3.83 Million EUR | 13.15% |
| 2015 Q3 | 3.39 Million EUR | -54.59% |
| 2015 Q2 | 7.47 Million EUR | 4.59% |
| 2014 Q4 | 5.28 Million EUR | -8.1% |
| 2014 FY | 27.69 Million EUR | 8.72% |
| 2014 Q1 | 6.88 Million EUR | 37.25% |
| 2014 Q2 | 9.76 Million EUR | 41.73% |
| 2014 Q3 | 5.75 Million EUR | -41.04% |
| 2013 Q4 | 5.01 Million EUR | -5.3% |
| 2013 FY | 25.47 Million EUR | 17.51% |
| 2013 Q1 | 5.98 Million EUR | -26.03% |
| 2013 Q2 | 9.16 Million EUR | 53.09% |
| 2013 Q3 | 5.29 Million EUR | -42.19% |
| 2012 Q4 | 8.09 Million EUR | 99.14% |
| 2012 FY | 21.67 Million EUR | 14.18% |
| 2012 Q1 | 5.4 Million EUR | 7.17% |
| 2012 Q3 | 4.06 Million EUR | -50.26% |
| 2012 Q2 | 8.17 Million EUR | 51.1% |
| 2011 Q4 | 5.04 Million EUR | 60.12% |
| 2011 Q2 | 8.93 Million EUR | 78.31% |
| 2011 Q3 | 3.15 Million EUR | -64.7% |
| 2011 FY | 18.98 Million EUR | -26.99% |
| 2011 Q1 | 5 Million EUR | 558.61% |
| 2010 Q3 | 6.77 Million EUR | -52.21% |
| 2010 Q1 | 6.13 Million EUR | 0.0% |
| 2010 Q4 | -1.09 Million EUR | -116.11% |
| 2010 FY | 26 Million EUR | 87.09% |
| 2010 Q2 | 14.18 Million EUR | 131.13% |
| 2009 FY | 13.89 Million EUR | -50.92% |
| 2008 FY | 28.32 Million EUR | 53.6% |
| 2007 FY | 18.43 Million EUR | 427.86% |
| 2006 FY | 3.49 Million EUR | -100.0% |
| 2005 FY | 291.58 Billion EUR | 46495.19% |
| 2004 FY | 625.79 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Atrys Health, S.A. | -1.58 Million EUR | 14022.503% |
| Biotechnologies Assets SA | 2.65 Million EUR | -8198.854% |
| Pharma Mar, S.A. | -3.82 Million EUR | 5855.265% |